Klinische Studie BAY 22615 SOHO 02 – Lunge und Bronchien
Offizieller Studientitel: A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations DE ↗
Studieninformationen
- Phase
- Phase III
- Organsystem
- Lunge und Bronchien
- Histologischer Typ
- NSCLC
- Molekulare Marker
- HER2/neu
- Therapiesetting
- Metastasiert
- Therapielinie
- 1st line
- Pädiatrische Studie
- Nein
- Sponsor
- –
Register & Identifikatoren
- ClinicalTrials.gov
- –
- EudraCT-Nr.
- 2024-511319-91-00
Standort & Kontakt
- Standort
- –
- Klinische Fachabteilung
- Charité Comprehensive Cancer Center (CCCC)
- Prüfarzt (PI)
- PD Dr. med. Damian Tobias Rieke Lang
- Ansprechpartner
- –
- –
- Telefon
- –